Modality
Radioligand
MOA
PCSK9i
Target
CD20
Pathway
Innate Imm
MDDGAPompe
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Jun 2027
Phase 2Current
NCT03240033
1,914 pts·GA
2018-04→2027-06·Terminated
1,914 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-281.2y awayPh2 Data· GA
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2
Termina…
Catalysts
Ph2 Data
2027-06-28 · 1.2y away
GA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03240033 | Phase 2 | GA | Terminated | 1914 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |